Project 2: Innate Immunity

项目2:先天免疫

基本信息

  • 批准号:
    10674303
  • 负责人:
  • 金额:
    $ 186.57万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-06-02 至 2023-06-01
  • 项目状态:
    已结题

项目摘要

Immunological memory is a hallmark of antigen-specific T and B lymphocytes. In contrast, the innate immune system is known to launch rapid, non-specific effector responses, which are short-lived. However, recent studies have proposed a form of immunological memory in the innate immune system, where innate cells can “remember” a pathogen encounter for several weeks to months. This phenomenon of “trained immunity” has been documented for NK cells, but less is known about its role in monocytes and dendritic cells (DCs). Innate memory has been suggested to be mediated via epigenetic changes in myeloid cells, but there are several fundamental questions about the mechanisms of innate memory. In this proposal, we will address the following questions in the context of vaccination with the live attenuated yellow fever vaccine 17D (YFV-17D) or acute dengue viral infection in humans, and in mechanistic studies in mice: 1. Unlike memory T and B cells, most DC and monocyte subsets are believed to have a relatively short lifespan of a few days. So how can epigenetic changes acquired by such short-lived cells mediate innate memory? Can subsets of myeloid-derived cells persist for several weeks after infection or vaccination? 2. To what extent is so called “innate memory” caused by the effects of an ongoing adaptive immune response (for example, via paracrine signaling), versus a cell intrinsic property of innate cells, similar to the classic phenomenon of immune memory exhibited by memory T or B cells? 3. Is there an enhanced response of DCs and monocytes, (similar to a memory response in the adaptive immune system), during secondary vaccination or infection? If so, what are the cellular and molecular mechanisms involved? We will address these questions in the following aims: Aim 1. Determining the innate response and regulatory landscape of DCs and monocytes in response to YFV-17D vaccination and dengue infection in humans. Aim 2: To determine the turnover rates of DCs and monocytes in response to YFV-17D vaccination in humans, using heavy water labeling. Aim 3: To define the mechanisms of innate memory induced by YFV-17D and adjuvants. Successful completion of these aims will further our mechanistic understanding of the phenomenon of innate memory, and offer novel strategies inducing broad and durable protection against diverse pathogens.
免疫记忆是抗原特异性T和B淋巴细胞的标志。相比之下,先天免疫力 众所周知,该系统会启动快速的、非特异性的效应器反应,这些反应是短暂的。然而,最近的研究 提出了一种先天免疫系统中的免疫记忆,在这种记忆中,先天细胞可以 “记住”病原体会在几周到几个月的时间里遭遇。这种“训练有素的免疫力”现象 已有文献证明其与NK细胞有关,但对其在单核细胞和树突状细胞(DC)中的作用知之甚少。先天的 记忆被认为是通过髓系细胞的表观遗传变化来调节的,但有几个 关于先天记忆机制的基本问题。在这项提案中,我们将解决以下问题 关于接种17D(YFV-17D)或急性减毒黄热病活疫苗的问题 登革热病毒在人类中的感染,以及在小鼠身上的机制研究: 1.与记忆T细胞和B细胞不同,大多数DC和单核细胞亚群的寿命被认为是相对较短的 几天的时间。那么,由这种短暂的细胞获得的表观遗传变化如何调节先天记忆呢? 在感染或接种后,髓系细胞亚群能持续几周吗? 2.所谓的“先天记忆”在多大程度上是由持续的适应性免疫反应造成的 (例如,通过旁分泌信号),而不是天然细胞的固有属性,类似于经典的 记忆T细胞或B细胞表现出的免疫记忆现象? 3.树突状细胞和单核细胞的反应是否增强(类似于适应性记忆反应 免疫系统),在二次疫苗接种或感染期间?如果是这样的话,细胞和分子是什么 涉及的机制是什么?我们将从以下几个方面解决这些问题: 目的1.确定树突状细胞和单核细胞对 YFV-17D疫苗接种和人类登革热感染。 目的:检测YFV-17D疫苗免疫小鼠后DC和单核细胞的转化率。 人类,使用重水标签。 目的:探讨YFV-17D及其佐剂诱导小鼠先天性记忆的机制。 这些目标的成功完成将进一步加深我们对先天现象的机械性理解 记忆,并提供新的策略,诱导广泛和持久的保护,对各种病原体。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BALI PULENDRAN其他文献

BALI PULENDRAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BALI PULENDRAN', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10584554
  • 财政年份:
    2022
  • 资助金额:
    $ 186.57万
  • 项目类别:
ADJUVANT COMPARISON AND CHARACTERIZATION
佐剂比较和表征
  • 批准号:
    10703849
  • 财政年份:
    2022
  • 资助金额:
    $ 186.57万
  • 项目类别:
Project 3: Mechanistic studies and comparisons of vaccines in preclinical models
项目3:临床前模型中疫苗的机理研究和比较
  • 批准号:
    10425032
  • 财政年份:
    2022
  • 资助金额:
    $ 186.57万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10419276
  • 财政年份:
    2022
  • 资助金额:
    $ 186.57万
  • 项目类别:
Adjuvant Comparison and Characterization (HIV)
佐剂比较和表征(HIV)
  • 批准号:
    10834856
  • 财政年份:
    2022
  • 资助金额:
    $ 186.57万
  • 项目类别:
Systems biological assessment of innate responses to vaccination
对疫苗接种先天反应的系统生物学评估
  • 批准号:
    10584566
  • 财政年份:
    2022
  • 资助金额:
    $ 186.57万
  • 项目类别:
Systems biological assessment of innate and adaptive immunity to vaccination
对疫苗接种的先天性和适应性免疫的系统生物学评估
  • 批准号:
    10419275
  • 财政年份:
    2022
  • 资助金额:
    $ 186.57万
  • 项目类别:
ADJUVANT COMPARISON AND CHARACTERIZATION
佐剂比较和表征
  • 批准号:
    10830900
  • 财政年份:
    2022
  • 资助金额:
    $ 186.57万
  • 项目类别:
Systems biological assessment of innate responses to vaccination
对疫苗接种先天反应的系统生物学评估
  • 批准号:
    10419279
  • 财政年份:
    2022
  • 资助金额:
    $ 186.57万
  • 项目类别:
Systems biological assessment of innate and adaptive immunity to vaccination
对疫苗接种的先天性和适应性免疫的系统生物学评估
  • 批准号:
    10879820
  • 财政年份:
    2022
  • 资助金额:
    $ 186.57万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 186.57万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 186.57万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 186.57万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 186.57万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 186.57万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 186.57万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 186.57万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 186.57万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 186.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 186.57万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了